#BEGIN_DRUGCARD DB04317

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C4H5Cl2O5P

# Chemical_IUPAC_Name:
3,3-dichloro-2-(phosphonomethyl)prop-2-enoic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
3,3-Dichloro-2-Phosphonomethyl-Acrylic Acid

# HET_ID:
DCO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C4H5Cl2O5P/c5-3(6)2(4(7)8)1-12(9,10)11/h1H2,(H,7,8)(H2,9,10,11)

# InChI_Key:
InChIKey=IBGSKYLUHGAGLB-UHFFFAOYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4317

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
234.959

# Molecular_Weight_Mono:
233.925165196

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1JQN

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.53

# Predicted_LogS:
-1.6

# Predicted_Water_Solubility:
5.36e+00 g/l

# Primary_Accession_No:
DB04317

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
367584

# PubChem_Substance_ID:
46508547

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01136

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)C(CP(O)(O)=O)=C(Cl)Cl

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:12 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X05903

# Drug_Target_1_GenBank_ID_Protein:
48666

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ppc

# Drug_Target_1_Gene_Sequence:
>2652 bp
ATGAACGAACAATATTCCGCATTGCGTAGTAATGTCAGTATGCTCGGCAAAGTGCTGGGA
GAAACCATCAAGGATGCGTTGGGAGAACACATTCTTGAACGCGTAGAAACTATCCGTAAG
TTGTCGAAATCTTCACGCGCTGGCAATGATGCTAACCGCCAGGAGTTGCTCACCACCTTA
CAAAATTTGTCGAACGACGAGCTGCTGCCCGTTGCGCGTGCGTTTAGTCAGTTCCTGAAC
CTGGCCAACACCGCCGAGCAATACCACAGCATTTCGCCGAAAGGCGAAGCTGCCAGCAAC
CCGGAAGTGATCGCCCGCACCCTGCGTAAACTGAAAAACCAGCCGGAACTGAGCGAAGAC
ACCATCAAAAAAGCAGTGGAATCGCTGTCGCTGGAACTGGTCCTCACGGCTCACCCAACC
GAAATTACCCGTCGTACACTGATCCACAAAATGGTGGAAGTGAACGCCTGTTTAAAACAG
CTCGATAACAAAGATATCGCTGACTACGAACACAACCAGCTGATGCGTCGCCTGCGCCAG
TTGATCGCCCAGTCATGGCATACCGATGAAATCCGTAAGCTGCGTCCAAGCCCGGTAGAT
GAAGCCAAATGGGGCTTTGCCGTAGTGGAAAACAGCCTGTGGCAAGGCGTACCAAATTAC
CTGCGCGAACTGAACGAACAACTGGAAGAGAACCTCGGCTACAAACTGCCCGTCGAATTT
GTTCCGGTCCGTTTTACTTCGTGGATGGGCGGCGACCGCGACGGCAACCCGAACGTCACT
GCCGATATCACCCGCCACGTCCTGCTACTCAGCCGCTGGAAAGCCACCGATTTGTTCCTG
AAAGATATTCAGGTGCTGGTTTCTGAACTGTCGATGGTTGAAGCGACCCCTGAACTGCTG
GCGCTGGTTGGCGAAGAAGGTGCCGCAGAACCGTATCGCTATCTGATGAAAAACCTGCGT
TCTCGCCTGATGGCGACACAGGCATGGCTGGAAGCGCGCCTGAAAGGCGAAGAACTGCCA
AAACCAGAAGGCCTGCTGACACAAAACGAAGAACTGTGGGAACCGCTCTACGCTTGCTAC
CAGTCACTTCAGGCGTGTGGCATGGGTATTATCGCCAACGGCGATCTGCTCGACACCCTG
CGCCGCGTGAAATGTTTCGGCGTACCGCTGGTCCGTATTGATATCCGTCAGGAGAGCACG
CGTCATACCGAAGCGCTGGGCGAGCTGACCCGCTACCTCGGTATCGGCGACTACGAAAGC
TGGTCAGAGGCCGACAAACAGGCGTTCCTGATCCGCGAACTGAACTCCAAACGTCCGCTT
CTGCCGCGCAACTGGCAACCAAGCGCCGAAACGCGCGAAGTGCTCGATACCTGCCAGGTG
ATTGCCGAAGCACCGCAAGGCTCCATTGCCGCCTACGTGATCTCGATGGCGAAAACGCCG
TCCGACGTACTGGCTGTCCACCTGCTGCTGAAAGAAGCGGGTATCGGGTTTGCGATGCCG
GTTGCTCCGCTGTTTGAAACCCTCGATGATCTGAACAACGCCAACGATGTCATGACCCAG
CTGCTCAATATTGACTGGTATCGTGGCCTGATTCAGGGCAAACAGATGGTGATGATTGGC
TATTCCGACTCAGCAAAAGATGCGGGAGTGATGGCAGCTTCCTGGGCGCAATATCAGGCA
CAGGATGCATTAATCAAAACCTGCGAAAAAGCGGGTATTGAGCTGACGTTGTTCCACGGT
CGCGGCGGTTCCATTGGTCGCGGCGGCGCACCTGCTCATGCGGCGCTGCTGTCACAACCG
CCAGGAAGCCTGAAAGGCGGCCTGCGCGTAACCGAACAGGGCGAGATGATCCGCTTTAAA
TATGGTCTGCCAGAAATCACCGTCAGCAGCCTGTCGCTTTATACCGGGGCGATTCTGGAA
GCCAACCTGCTGCCACCGCCGGAGCCGAAAGAGAGCTGGCGTCGCATTATGGATGAACTG
TCAGTCATCTCCTGCGATGTCTACCGCGGCTACGTACGTGAAAACAAAGATTTTGTGCCT
TACTTCCGCTCCGCTACGCCGGAACAAGAACTGGGCAAACTGCCGTTGGGTTCACGTCCG
GCGAAACGTCGCCCAACCGGCGGCGTCGAGTCACTACGCGCCATTCCGTGGATCTTCGCC
TGGACGCAAAACCGTCTGATGCTCCCCGCCTGGCTGGGTGCAGGTACGGCGCTGCAAAAA
GTGGTCGAAGACGGCAAACAGAGCGAGCTGGAGGCTATGTGCCGCGATTGGCCATTCTTC
TCGACGCGTCTCGGCATGCTGGAGATGGTCTTCGCCAAAGCAGACCTGTGGCTGGCGGAA
TACTATGACCAACGCCTGGTAGACAAAGCACTGTGGCCGTTAGGTAAAGAGTTACGCAAC
CTGCAAGAAGAAGACATCAAAGTGGTGCTGGCGATTGCCAACGATTCCCATCTGATGGCC
GATCTGCCGTGGATTGCAGAGTCTATTCAGCTACGGAATATTTACACCGACCCGCTGAAC
GTATTGCAGGCCGAGTTGCTGCACCGCTCCCGCCAGGCAGAAAAAGAAGGCCAGGAACCG
GATCCTCGCGTCGAACAAGCGTTAATGGTCACTATTGCCGGGATTGCGGCAGGTATGCGT
AATACCGGCTAA

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
1551850	Meinnel T, Schmitt E, Mechulam Y, Blanquet S: Structural and biochemical characterization of the Escherichia coli argE gene product. J Bacteriol. 1992 Apr;174(7):2323-31.
1765093	Terada K, Izui K: Site-directed mutagenesis of the conserved histidine residue of phosphoenolpyruvate carboxylase. His138 is essential for the second partial reaction. Eur J Biochem. 1991 Dec 18;202(3):797-803.
2016273	Terada K, Murata T, Izui K: Site-directed mutagenesis of phosphoenolpyruvate carboxylase from E. coli: the role of His579 in the catalytic and regulatory functions. J Biochem (Tokyo). 1991 Jan;109(1):49-54.
2677392	Inoue M, Hayashi M, Sugimoto M, Harada S, Kai Y, Kasai N, Terada K, Izui K: First crystallization of a phosphoenolpyruvate carboxylase from Escherichia coli. J Mol Biol. 1989 Aug 5;208(3):509-10.
3889833	Izui K, Miwa T, Kajitani M, Fujita N, Sabe H, Ishihama A, Katsuki H: Promoter analysis of the phosphoenolpyruvate carboxylase gene of Escherichia coli. Nucleic Acids Res. 1985 Jan 11;13(1):59-71.
6086598	Fujita N, Miwa T, Ishijima S, Izui K, Katsuki H: The primary structure of phosphoenolpyruvate carboxylase of Escherichia coli. Nucleotide sequence of the ppc gene and deduced amino acid sequence. J Biochem (Tokyo). 1984 Apr;95(4):909-16.
7490260	Yano M, Terada K, Umiji K, Izui K: Catalytic role of an arginine residue in the highly conserved and unique sequence of phosphoenolpyruvate carboxylase. J Biochem (Tokyo). 1995 Jun;117(6):1196-200.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9927652	Kai Y, Matsumura H, Inoue T, Terada K, Nagara Y, Yoshinaga T, Kihara A, Tsumura K, Izui K: Three-dimensional structure of phosphoenolpyruvate carboxylase: a proposed mechanism for allosteric inhibition. Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):823-8.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3339

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
99064

# Drug_Target_1_Name:
Phosphoenolpyruvate carboxylase

# Drug_Target_1_Number_of_Residues:
883

# Drug_Target_1_PDB_ID:
1JQN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00311	PEPcase

# Drug_Target_1_Protein_Sequence:
>Phosphoenolpyruvate carboxylase
MNEQYSALRSNVSMLGKVLGETIKDALGEHILERVETIRKLSKSSRAGNDANRQELLTTL
QNLSNDELLPVARAFSQFLNLANTAEQYHSISPKGEAASNPEVIARTLRKLKNQPELSED
TIKKAVESLSLELVLTAHPTEITRRTLIHKMVEVNACLKQLDNKDIADYEHNQLMRRLRQ
LIAQSWHTDEIRKLRPSPVDEAKWGFAVVENSLWQGVPNYLRELNEQLEENLGYKLPVEF
VPVRFTSWMGGDRDGNPNVTADITRHVLLLSRWKATDLFLKDIQVLVSELSMVEATPELL
ALVGEEGAAEPYRYLMKNLRSRLMATQAWLEARLKGEELPKPEGLLTQNEELWEPLYACY
QSLQACGMGIIANGDLLDTLRRVKCFGVPLVRIDIRQESTRHTEALGELTRYLGIGDYES
WSEADKQAFLIRELNSKRPLLPRNWQPSAETREVLDTCQVIAEAPQGSIAAYVISMAKTP
SDVLAVHLLLKEAGIGFAMPVAPLFETLDDLNNANDVMTQLLNIDWYRGLIQGKQMVMIG
YSDSAKDAGVMAASWAQYQAQDALIKTCEKAGIELTLFHGRGGSIGRGGAPAHAALLSQP
PGSLKGGLRVTEQGEMIRFKYGLPEITVSSLSLYTGAILEANLLPPPEPKESWRRIMDEL
SVISCDVYRGYVRENKDFVPYFRSATPEQELGKLPLGSRPAKRRPTGGVESLRAIPWIFA
WTQNRLMLPAWLGAGTALQKVVEDGKQSELEAMCRDWPFFSTRLGMLEMVFAKADLWLAE
YYDQRLVDKALWPLGKELRNLQEEDIKVVLAIANDSHLMADLPWIAESIQLRNIYTDPLN
VLQAELLHRSRQAEKEGQEPDPRVEQALMVTIAGIAAGMRNTG

# Drug_Target_1_Reaction:
phosphate + oxaloacetate = H2O + phosphoenolpyruvate + CO2

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Through the carboxylation of phosphoenolpyruvate (PEP) it forms oxaloacetate, a four-carbon dicarboxylic acid source for the tricarboxylic acid cycle

# Drug_Target_1_SwissProt_ID:
P00864

# Drug_Target_1_SwissProt_Name:
CAPP_ECOLI

# Drug_Target_1_Synonyms:
EC 4.1.1.31
PEPC
PEPCase

# Drug_Target_1_Theoretical_pI:
5.40

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB04317
